Jun Yong Choi

Dr. Jun Yong Choi

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2020 in Science Immunology
Verified
Journal Article
Open access
PDF file
JLJeong Seok Lee
Jeong Seok Lee
SPSeongwan Park
Seongwan Park
HJHye Won Jeong
Hye Won Jeong
JAJin Young Ahn
Jin Young Ahn
SCSeong Jin Choi
Seong Jin Choi
ESEui-Cheol Shin
Eui-Cheol Shin
Single-cell RNA sequencing of blood immune cells reveals type I interferon–associated hyper-inflammation in severe COVID-19.

1 January 2021 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
JCJun Yong Choi
Jun Yong Choi
DSDavey M. Smith
Davey M. Smith
Choi JY, et al. Yonsei Med J. 2021 Nov;62(11):961-968. https://doi.org/10.3349/ymj.2021.62.11.961

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JAJin Young Ahn
Jin Young Ahn
YSYujin Sohn
Yujin Sohn
SLSu Hwan Lee
Su Hwan Lee
YCYunsuk Cho
Yunsuk Cho
JHJongHoon Hyun
JongHoon Hyun
JCJun Yong Choi
Jun Yong Choi
Ahn JY, et al. J Korean Med Sci. 2020 Feb;35(14):e149. https://doi.org/10.3346/jkms.2020.35.e149

15 December 2011 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
DCDoo Ryeon Chung
Doo Ryeon Chung
JSJae-Hoon Song
Jae-Hoon Song
SKSo Hyun Kim
So Hyun Kim
VTVisanu Thamlikitkul
Visanu Thamlikitkul
SHShao-Guang Huang
Shao-Guang Huang
KPKyong Ran Peck
Kyong Ran Peck
Rationale: Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) remain important causes of morbidity and mortality. Increasing antimicrobial resistance has aroused the concern of the failure of antibiotic treatment. Objectives: To determine the distribution of the bacterial isolates of HAP and VAP, their antimicrobial resistance patterns, and impact of discordant antibiotic therapy on clinical outcome in Asian countries Methods: A prospective surveillance study was conducted in 73 hospitals in 10 Asian countries from 2008–2009. A total of 2,554 cases with HAP or VAP in adults were enrolled and 2,445 bacterial isolates were collected from 1,897 cases. Clinical characteristics and antimicrobial resistance profiles were analyzed. Measurement and Main Results: Major bacterial isolates from HAP and VAP cases in Asian countries were Acinetobacter spp., Pseudomonas aeruginosa, Staphylococcus aureus, and Klebsiella pneumoniae. Imipenem resistance rates of Acinetobacter and P. aeruginosa were 67.3% and 27.2%, respectively. Multidrug-resistant rates were 82% and 42.8%, and extensively drug-resistant rates were 51.1% and 4.9%. Multidrug-resistant rate of K. pneumoniae was 44.7%. Oxacillin resistance rate of S. aureus was 82.1%. All-cause mortality rate was 38.9%. Discordant initial empirical antimicrobial therapy increased the likelihood of pneumonia-related mortality (odds ratio, 1.542; 95% confidence interval, 1.127–2.110). Conclusions: Acinetobacter spp., P. aeruginosa, S. aureus, and K. pneumoniae are the most frequent isolates from adults with HAP or VAP in Asian countries. These isolates are highly resistant to major antimicrobial agents, which could limit the therapeutic options in the clinical practice. Discordant initial empirical antimicrobial therapy significantly increases the likelihood of pneumonia-related mortality.

1 January 2021 in Immunity
Verified
Journal Article
Closed access
MRMin-Seok Rha
Min-Seok Rha
HJHye Won Jeong
Hye Won Jeong
JKJae-Hoon Ko
Jae-Hoon Ko
SCSeong Jin Choi
Seong Jin Choi
ISIn-Ho Seo
In-Ho Seo
ESEui-Cheol Shin
Eui-Cheol Shin

9 December 2013 in Critical Care
Verified
Journal Article
Open access
PDF file
CKChan Ho Kim
Chan Ho Kim
JPJung Tak Park
Jung Tak Park
EKEun Jin Kim
Eun Jin Kim
JHJae Hyun Han
Jae Hyun Han
JHJi Suk Han
Ji Suk Han
HOHyung Jung Oh
Hyung Jung Oh
Introduction: A potential independent association was recently demonstrated between high red blood cell distribution width (RDW) and the risk of all-cause mortality in critically ill patients, although the mechanism underlying this relationship remains unclear. Little is known about the impact changes in RDW may have on survival in critically ill patients. Therefore, we investigated the prognostic significance of changes in RDW during hospital stay in patients with severe sepsis or septic shock. Methods: We prospectively enrolled 329 patients who were admitted to the emergency department (ED) and received a standardized resuscitation algorithm (early-goal directed therapy) for severe sepsis or septic shock. The relationship between the changes in RDW during the first 72 hours after ED admission and all-cause mortality (28-day and 90-day) were analyzed by categorizing the patients into four groups according to baseline RDW value and ΔRDW72hr-adm (RDW at 72 hours – RDW at baseline). Results: The 28-day and 90-day mortality rates were 10% and 14.6%, respectively. Patients with increased RDW at baseline and ΔRDW72hr-adm >0.2% exhibited the highest risks of 28-day and 90-day mortality, whereas the patients with normal RDW level at baseline and ΔRDW72hr-adm ≤0.2% (the reference group) had the lowest mortality risks. For 90-day mortality, a significantly higher mortality risk was observed in the patients whose RDW increased within 72 hours of ED admission (normal RDW at baseline and ΔRDW72hr-adm >0.2%), compared to the reference group. These associations remained unaltered even after adjusting for age, sex, Sequential Organ Failure Assessment (SOFA) score, Charlson Comorbidity Index, renal replacement therapy, albumin, hemoglobin, lactate, C-reactive protein and infection sites in multivariable models. Conclusions: We found that an increase in RDW from baseline during the first 72 hours after hospitalization is significantly associated with adverse clinical outcomes. Therefore, a combination of baseline RDW value and an increase in RDW can be a promising independent prognostic marker in patients with severe sepsis or septic shock.